DAYTIME FLUCTUATIONS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN POPULATIONS WITH HIGH PAI-1 LEVELS

被引:0
|
作者
JUHANVAGUE, I [1 ]
ALESSI, MC [1 ]
RACCAH, D [1 ]
AILLAUD, MF [1 ]
BILLEREY, M [1 ]
ANSALDI, J [1 ]
PHILIPJOET, C [1 ]
VAGUE, P [1 ]
机构
[1] CHU TIMONE, SERV DIABETOL, F-13385 MARSEILLE, FRANCE
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mechanism underlying diurnal variations in PAI-1 as well as the cellular origin of PAI-1 in subjects with high PAI-1 levels are unknown. We evaluated diurnal changes (8:00 am vs 4:00 pm) in PAI-1 (functional and immunological assays), t-PA Ag and t-PA/PAI-1 complex levels in controls and subjects with high PAI-1 levels. Three test groups were recruited among obese hyperinsulinemic subjects, emergency care unit patients with inflammatory syndrome or infection and pregnant women. The classical afternoon decrease of PAI-1 level was observed in controls and obese subjects but its amplitude was greater in the latter. The decrease in t-PA Ag and t-PA/PAI-1 complex levels was the same in controls and in obese. As, in previous studies, elevated PAI-I levels have been correlated with insulin resistance and a decrease in insulin sensibility has been described in the early morning, it is proposed that this "dawn phenomenon" could be implicated in the circadian variations of PAI-1 in controls and could be amplified in obese subjects. Great variability in PAI-1, t-PA Ag or t-PA/PAI-1 complex levels was observed in patients with acute inflammatory syndrome or infection for whom classical biorhythms are suppressed. No diurnal changes in PAI-1 and other fibrinolytic parameters were observed in patients with inflammatory syndrome or in pregnant women suggesting that other sources and/or other regulatory mechanisms of PAI-1 production are involved.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [21] INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) WITH VITRONECTIN
    SALONEN, EM
    VAHERI, A
    POLLANEN, J
    STEPHENS, R
    ANDREASEN, P
    MAYER, M
    DANO, K
    GAILIT, J
    RUOSLAHTI, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1989, 264 (11) : 6339 - 6343
  • [22] DISTRIBUTION OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) IN TISSUES
    SIMPSON, AJ
    BOOTH, NA
    MOORE, NR
    BENNETT, B
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1991, 44 (02) : 139 - 143
  • [23] REVERSIBLE INTERACTIONS BETWEEN PLASMINOGEN ACTIVATORS (PAS) AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1)
    KANEKO, M
    SAKURAMA, T
    MURAKAMI, T
    MATSUDA, M
    SAKATA, Y
    MIMURO, J
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1326 - 1326
  • [24] ANALYSIS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN ISCHEMIC HEART-DISEASE
    WATANABE, M
    UNO, M
    TAKADA, O
    TSUJI, H
    TAKABUCHI, H
    KOBAYASHI, K
    SHIRAI, K
    SAWADA, S
    TOYODA, T
    NAKAGAWA, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 401 - 401
  • [25] ELISA SYSTEMS FOR ACTIVE AND TOTAL PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) ANTIGEN
    RESCH, I
    KRUTISCH, G
    GEIGER, M
    BINDER, BR
    [J]. THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 299 - 299
  • [26] DETERMINATION OF THE VITRONECTIN BINDING-SITE ON PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1)
    VANMEIJER, M
    GEBBINK, RK
    PREISSNER, KT
    PANNEKOEK, H
    [J]. FEBS LETTERS, 1994, 352 (03) : 342 - 346
  • [28] STRUCTURE OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) AND ITS FUNCTION IN FIBRINOLYSIS - AN UPDATE
    VANMEIJER, M
    PANNEKOEK, H
    [J]. FIBRINOLYSIS, 1995, 9 (05) : 263 - 276
  • [29] ETHNIC-DIFFERENCES IN THE ASSOCIATION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) WITH NIDDM
    NAGI, D
    YUDKIN, J
    [J]. DIABETES, 1994, 43 : A37 - A37
  • [30] PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN PLASMA - ITS ROLE IN THROMBOTIC DISEASE
    WIMAN, B
    [J]. THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1138 - 1138